Bruce N. Jacobs - Jun 3, 2021 Form 4 Insider Report for Kymera Therapeutics, Inc. (KYMR)

Role
Chief Financial Officer
Signature
/s/ Bruce N. Jacobs
Stock symbol
KYMR
Transactions as of
Jun 3, 2021
Transactions value $
-$447,895
Form type
4
Date filed
6/4/2021, 04:16 PM
Next filing
Sep 3, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYMR Common Stock Options Exercise $20.8K +10K +137.82% $2.08* 17.3K Jun 3, 2021 Direct F1
transaction KYMR Common Stock Sale -$257K -5.51K -32.39% $46.66 11.5K Jun 3, 2021 Direct F2, F3
transaction KYMR Common Stock Sale -$212K -4.49K -38.25% $47.13 7.26K Jun 3, 2021 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYMR Stock Option (Right to Buy) Award $0 -10K -4.35% $0.00 220K Jun 3, 2021 Common Stock 10K $2.08 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This number includes 256 shares acquired under the Registrant's employee stock purchase plan for the period ended May 31, 2021.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $45.93 to $46.92. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.93 to $47.43. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5 Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.